Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477

Name:	us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Acquisitions Purchase Price (Details) - USD ($) $ in Millions		2 Months Ended	9 Months Ended	12 Months Ended
	Oct. 25, 2018	Dec. 31, 2018	Sep. 29, 2018	Dec. 31, 2017
Other [Member]
Purchase Price
Total Purchase Price			$ 65
Advanced Bioprocessing business [Member]
Net Assets Acquired [Abstract]
Revenue Reported by Acquired Entity				$ 100
Scenario, Forecast [Member] \| Gatan, Inc. [Member]
Purchase Price
Cash paid		$ 925
Subsequent Event [Member] \| Advanced Bioprocessing business [Member]
Purchase Price
Cash paid	$ 477